Treatment-resistant obsessive-compulsive disorder (OCD): Current knowledge and open questions

Clinical Neuropsychiatry

Volumn 10, Issue 1, 2013, Pages 19-30

  Albert, Umberto ^a   Aguglia, Andrea ^a   Bramante, Stefano ^a   Bogetto, Filippo ^a   Maina, Giuseppe ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Augmentation; Obsessive compulsive disorder; Switch; Treatment resistant OCD

Indexed keywords

ARIPIPRAZOLE; CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ALGORITHM; ARTICLE; COGNITIVE THERAPY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERTENSION; MONOTHERAPY; OBSESSIVE COMPULSIVE DISORDER; OPEN STUDY; OPTIMAL DRUG DOSE; PRACTICE GUIDELINE; SIDE EFFECT; TREATMENT INDICATION; WEIGHT GAIN;

EID: 84876999823     PISSN: 17244935     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (134)

1. Ackerman DL, Greenland S, Bystritsky A (1998). Clinical characteristics of response to fuoxetine treatment of obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 18, 3, 185-192.
2. Alacron RD, Libb JW, Spitler D (1993). A predictive study of obsessive compulsive response to clomipramine. Journal of Clinical Psychopharmacology 13, 210-213.
3. Albert U, Aguglia E, Maina G, Bogetto F (2002). Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. Journal of Clinical Psychiatry 63, 11, 1004-1009.
4. Albert U, Maina G, Forner F, Bogetto F (2003). Cognitive-behavioral therapy in obsessive-compulsive disorder patients partially unresponsive to SRIs. European Neuropsychopharmacology 13, suppl 4, S357.
5. Albert U, Maina G, Saracco P, Bogetto F (2006). Multifamily psychoeducational Intervention (MPI) for obsessive-compulsive study: a pilot study. Epidemiologia e Psichiatria Sociale 15, 1, 70-75.
6. Albert U, Salvi V, Saracco P, Bogetto F, Maina G (2007). Health-related quality of life among frst degree relatives of patients with obsessive-compulsive disorder in Italy. Psychiatry Service 58, 7, 970-976.
7. Albert U, Maina G, Bogetto F, Chiarle A, Mataix-Cols D (2010). Clinical predictors of health-related quality of life in obsessive-compulsive disorder. Comprehensive Psychiatry 51, 2, 193-200.
8. Albert U, Aguglia A, Bogetto F, Cieri L, Daniele M, Maina G, Necci R, Parena A, Salvati L, Tundo A (2012a). Effectiveness of cognitive-behavioral therapy addition to pharmacotherapy in resistant obsessive-compulsive disorder: a multicenter study. Psychotherapy and Psychosomatics 81, 6, 383-385.
9. Albert U, Aguglia A, Chiarle A, Bogetto F, Maina G (2012b). Metabolic syndrome and obsessive-compulsive disorder: a naturalistic Italian study. General Hospital Psychiatry, in press.
10. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text revision. American Psychiatric Press, Washington, DC.
11. American Psychiatric Association (2007). Practice Guideline for the treatment of patients with obsessive-compulsive disorder. American Psychiatric Association, Arlington, VA.
12. Amiaz R, Fostick L, Gershon A, Zohar J (2008). Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. European Neuropsychopharmacology 18, 6, 455-461.
13. Anand N, Sudhir PM, Bada Math S, Thennarasu K, Reddy YCJ (2011). Cognitive behaviour therapy in medication non-responders with obsessive-compulsive disorder: a prospective 1-year follow-up study. Journal of Anxiety Disorders 25, 7, 939-945.
14. Atmaca M, Kuloglu M, Tezcan E, Gecici O (2002). Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol 24, 10, 1439-1445.
15. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU; British Association for Psychopharmacology (2005). Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 19, 567-596.
16. Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ, Zohar J, Hollander E, Kasper S, Möller HJ, Bandelow B, Allgulander C, Ayuso-Gutierrez J, Baldwin DS, Buenvicius R, Cassano G, Fineberg N, Gabriels L, Hindmarch I, Kaiya H, Klein DF, Lader M, Lecrubier Y, Lépine JP, Liebowitz MR, Lopez-Ibor JJ, Marazziti D, Miguel EC, Oh KS, Preter M, Rupprecht R, Sato M, Starcevic V, Stein DJ, van Ameringen M, Vega J (2008). WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disoders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision. World Journal of Biological Psychiatry 9, 4, 248-312.
17. Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, Möller HJ; WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD and PTSD (2012). Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder in primary care. International Journal of Psychiatry in Clinical Practice 16, 77-84.
18. Barr LC, Goodman WK, Anand A, McDougle CJ, Price LH (1997). Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. American Journal of Psychiatry 154, 9, 1293-1295.
19. Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E (2011). Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. Journal of Clinical Psychiatry 72, 5, 716-721.
20. Bloch MH, Landeros-Weisenberger A, Kelmedi B, Coric V, Bracken MB, Leckman JF (2006). A systematic review: antipsychotic augmentation with treatment-refractory obsessive-compulsive disorder. Molecular Psychiatry 11, 622-632.
21. Bloch MH, McGuire J, Landeros-Weisenberger A, Leckman JF, Pittenger C (2010). Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Molecular Psychiatry 15, 8, 850-855.
22. Bruno A, Micò U, Pandolfo G, Mallamace D, Abenavoli E, Di Nardo F, D'Arrigo C, Spina E, Zoccali RA, Muscatello MR (2012). Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Journal of Psychopharmacology 26, 11, 1456-1462.
23. Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S (2004). Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. Journal of Clinical Psychiatry 65, 4, 565-568.
24. Canadian Psychiatric Association (2006). Clinical practice guidelines. Management of anxiety disorders. Canadian Journal of Psychiatry 51, 9S-91S.
25. Carey PD, Vythilingum B, Seedat S, Muller JE, van Ameringen M, Stein DJ (2005). Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study. BMC Psychiatry 5, 5.
26. Crockett BA, Churchill E, Davidson JR (2004). A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder. Annals of Clinical Psychiatry 16, 3, 127-132.
27. Dannon PN, Sasson Y, Hirschmann S, Iancu I, Grunhaus LJ, Zohar J (2000). Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial. European Neuropsychopharmacology 10, 3, 165-169.
28. Deacon BJ, Abramowitz JS (2004). Cognitive and behavioral treatments for anxiety disorders: a review of meta-analytic findings. Journal of Clinical Psychology 60, 4, 429-441.
29. De Haan E, van Oppen P, van Balkom AJ, Spinhoven P, Hoogduin KA, Van Dick R (1997). Prediction of outcome and early vs late improvement in OCD patients treated with cognitive behavior therapy and pharmacotherapy. Acta Psychiatrica Scandinavica 96, 354-361.
30. Dell'Osso B, Mundo E, Marazziti D, Altamura AC (2008). Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series. Journal of Psychopharmacology 22, 2, 210-213.
31. Denys D, van der Wee N, van Megen HJ, Westenberg HG (2003). A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 23, 6, 568-575.
32. Denys D, Zohar J, Westenberg HG (2004a). The role of dopamine in Obsessive-compulsive disorder: preclinical and clinical evidence. Journal of Clinical Psychiatry 65, suppl 14, 11-17.
33. Denys D, De Geus F, Van Megen HJ, Westenberg HG (2004b). A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. Journal of Clinical Psychiatry 65, 1040-1048.
34. Diniz JB, Shavitt RG, Pereira CA, Hounie AG, Pimentel I, Koran LM, Dainesi SM, Miguel EC (2010). Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial. Journal of Psychopharmacology 24, 3, 297-307.
35. Diniz JB, Shavitt RG, Fossaluza V, Koran L, Pereira CA, Miguel EC (2011). A double-blind, randomized, controlled trial of fuoxetine plus quetiapine or clomipramine versus fuoxetine plus placebo for obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 31, 6, 763-768.
36. Dold M, Aigner M, Lanzenberger R, Kasper S (2012). Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. International Journal of Neuropsychopharmacology 1-18.
37. Eddy KT, Dutra L, Bradley R, Westen D (2004). A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clinical Psychology Review 24, 8, 1011-1030.
38. Erzegovesi S, Cavellini MC, Cavedini P, Diaferia G, Locatelli M, Bellodi L (2001). Clinical predictors of drug response in obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 21, 272-275.
39. Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L (2005). Low-dose risperidone augmentation of fuvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. European Neuropsychopharmacology 15, 1, 69-74.
40. Fallon BA, Campeas R, Schneier FR, Hollander E, Feerick J, Hatterer J, Goetz D, Davies S, Liebowitz MR (1992). Open trial of Intravenous clomipramine in fve treatment-refractory patients with obsessive-compulsive disorder. The Journal of Neuropsychiatry and Clinical Neurosciences 4, 1, 70-75.
41. Fallon BA, Liebowitz MR, Campeas R, Schneier FR, Marshall R, Davies S, Goetz D, Klein DF (1998). Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine. Archives of General Psychiatry 55, 918-924.
42. Figueroa Y, Rosenberg DR, Birmaher B, Keshavan MS (1998). Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents. Journal of Child and Adolescent of Psychopharmacology 8, 1, 61-67.
43. Fineberg NA, Sivakumaran T, Roberts A, Gale T (2005). Adding quetiapine to SSRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. International Clinical Psychopharmacology 20, 223-226.
44. Fineberg NA, Gale TM, Sivakumaran T (2006). A review of antipsychotics in the treatment of obsessive compulsive disorder. Journal of Psychopharmacology 21, 1, 97-103.
45. Fineberg NA, Tonnoir B, Lemming O, Stein DJ (2007). Escitalopram prevents relapse of obsessive-compulsive disorder. European Neuropsychopharmacology 17, 430-437.
46. Fisher PL, Wells A (2005). How effective are cognitive and behavioural treatments for obsessive-compulsive disorder? A clinical signifcance analysis. Behaviour Research and Therapy 43, 12, 1543-1558.
47. Fontenelle IS, Fontenelle LF, Borges MC, Prazeres AM, Rangé BP, Mendlowicz M V, Versiani M (2010). Quality of life and symptom dimensions of patients with obsessive-compulsive disorder. Psychiatry Research 179, 2, 198-203.
48. Fornaro M (2011). Switching from serotonin reuptake inhibitors to agomelatine in patients with refractory obsessive-compulsive disorder: a 3 month follow-up case series. Annals of General Psychiatry 10, 1, 5.
49. Fux M, Benjamin J, Belmaker RH (1999). Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study. International Journal of Neuropsychopharmacology 2, 3, 193-195.
50. Ghaemi SN, Wingo AP, Filkowski MA, Baldessarini RJ (2008). Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefts and risks. Acta Psychiatrica Scandinavica 118, 5, 347-356.
51. Goddard AW, Shekhar A, Whiteman AF, McDougle CJ (2008). Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder. Drug Discovery Today 13, 325-332.
52. Goodman WK, McDougle CJ, Barr LC, Aronson SC, Price LH (1993). Biological approaches to treatment-resistant obsessive compulsive disorder. Journal of Clinical Psychiatry 54, suppl 6, 16-26.
53. Goodman WK, Ward H, Kablinger A, Murphy T (1997). Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions. Journal of Clinical Psychiatry 58, 5, 32-49.
54. Grady TA, Pigott TA, L'Heureux F, Hill JL, Bernstein SE, Murphy DL (1993). Double-blind study of adjuvant buspirone for fuoxetine-treated patients with obsessive-compulsive disorder. American Journal of Psychiatry 150, 5, 819-821.
55. Greist JH, Jefferson JW (1998). Pharmacotherapy for obsessive-compulsive disorder. British Journal of Psychiatry 173, 64-70.
56. Grover S, Dutt A (2011). Perceived burden and quality of life of caregivers in obsessive-compulsive disorder. Psychiatry and Clinical Neurosciences 65, 5, 416-422.
57. Gupta AK, Prieto-Merino D, Dahlöf B, Sever PS, Poulter NR; ASCOT Investigators (2011). Metabolic syndrome, impaired fasting glucose and obesity, as predictors of incident diabetes in 14.120 hypertensive patients of ASCOT-BPLA: comparison of their relative predictability using a novel approach. Diabetic Medicine 28, 8, 941-947.
58. Hollander E, Baldini Rossi N, Sood E, Pallanti S (2003a). Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. International Journal of Neuropsychopharmacology 6, 4, 397-401.
59. Hollander E, Friedberg J, Wasserman S, Allen A, Birnbaum M, Koran LM (2003b). Venlafaxine in treatment-resistant obsessive-compulsive disorder. Journal of Clinical Psychiatry 64, 5, 546-550.
60. Hollander E, Stein DJ, Fineberg NA, Marteau F, Legault M (2010). Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse. Journal of Clinical Psychiatry 71, 6, 784-792.
61. Kampman M, Keijsers GP, Hoogduin CA, Verbraak MJ (2002). Addition of cognitive-behaviour therapy for obsessive-compulsive disorder patients non-responding to fuoxetine. Acta Psychiatrica Scandinavica 106, 4, 314-319.
62. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 62, 617-627.
63. Khang YH, Cho SI, Kim HR (2010). Risks for cardiovascular disease, stroke, ischaemic heart disease, and diabetes mellitus associated with the metabolic syndrome using the new harmonised defnition: fndings from nationally representative longitudinal data from an Asian population. Atherosclerosis 213, 2, 579-585.
64. Komossa K, Depping AM, Meyer M, Kissling W, Leucht S (2010). Second-generation antipsychotics for obsessive-compulsive disorder. Cochrane Database of Systematic Reviews 8, CD008141.
65. Koo MS, Kim EJ, Roh D, Kim CH (2010). Role of dopamine in the pathophysiology and treatment of obsessive-compulsive disorder. Expert Review of Neurotherapeutics 10, 2, 275-290.
66. Koran LM, Sallee FR, Pallanti S (1997). Intravenous pulse loading of clomipramine produce rapid beneft in obsessive-compulsive disorder. American Journal of Psychiatry 154, 396-401.
67. Koran LM, Saxena S (2000). Issues and strategies in treating refractory obsessive-compulsive disorder. CNS Spectrum 5, 6, suppl 4, 24-31.
68. Koran LM, Quirk T, Lorberbaum JP, Elliott M (2001). Mirtazapine treatment of obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 21, 5, 537-539.
69. Koran LM, Gamel NN, Choung HW, Smith EH, Aboujaoude EN (2005). Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. Journal of Clinical Psychiatry 66, 4, 515-520.
70. Koran LM, Aboujauode E, Ward H, Shapira NA, Sallee FR, Gamel N, Elliott M (2006). Pulse-loaded intravenous clomipramine in treatment-resistant obsessive compulsive disorder. Journal of Clinical Psychopharmacology 26, 79-83.
71. Koran LM, Aboujaoude E, Gamel N (2009). Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. Journal of Clinical Psychiatry 70, 11, 1530-1535.
72. Kordon A, Wahl K, Koch N, Zurowski B, Anlauf M, Vielhaber K, Kahl KG, Broocks A, Voderholzer U, Hohagen F (2008). Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. Journal of Clinical Psychopharmacology 28, 5, 550-554.
73. Jenike MA (2004). Clinical practice. Obsessive-compulsive disorder. New England Journal of Medicine 350, 259-265.
74. Joseph J, Svartberg J, Njølstad I, Schirmer H (2011). Risk factors for type 2 diabetes in groups stratifed according to metabolic syndrome: a 10-year follow-up of the Tromsø Study. European Journal of Epidemiology 26, 2, 117-124.
75. Maina G, Albert U, Bogetto (2001). Venlafaxine in treatment resistant OCD patients: a single-blind, randomised, controlled study versus clomipramine and citalopram. European Neuropsychopharmacology 11, suppl 2, S66.
76. Maina G, Albert U, Ziero S, Bogetto F (2003). Antipsychotic augmentation for the treatment-resistant obsessive-compulsive disorder: what if antipsychotic is discontinued? International Clinical Psychopharmachology 18, 23-28.
77. Maina G, Saracco P, Albert U (2006). Family-focused treatments for obsessive-compulsive disorder. Clinical Neuropsychiatry 3, 6, 382-390.
78. Maina G, Pessina E, Albert U, Bogetto F (2008). 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. European Neuropsychopharmacology 18, 5, 364-372.
79. Marazziti D, Dell'Osso L, Gemignani A, Ciapparelli A, Presta S, Nasso ED, Pfanner C, Cassano GB (2001). Citalopram in refractory obsessive-compulsive disorder: an open study. International Clinical Psychopharmacology 16, 215-219.
80. Marazziti D, Pfanner C, Dell'Osso B, Ciapparelli A, Presta S, Corretti G, Di Nasso E, Mungai F, Dell'Osso L (2005). Augmentation strategy with olanzapine in resistano obsessive-compulsive disorder: an Italian long-term open-label study. Journal of Psychopharmacology 19, 4, 392-394.
81. Marazziti D, Golia F, Consoli G, Presta S, Pfanner C, Carlini M, Mungai F, Catena Dell'osso M (2008). Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients. CNS Spectrum 13, 11, 971-976.
82. Marazziti D, Carlini M, Dell'Osso L (2012a). Treatment srategies of obsessive-compulsive disorder and panic disorder/ agoraphobia. Current Topics in Medicinal Chemistry 12, 4, 238-253.
83. Marazziti D, Baroni S, Faravelli L, Giannaccini G, Massimetti G, Palego L, Catena-Dell-Osso M (2012b). Plasma clomipramine levels in adult patients with obsessive-compulsive disorder. International Clinical Psychopharmacology 27, 1, 55-60.
84. March J, Frances A, Carpenter D, Kahn D, eds. (1997). The Expert Consensus Guidelines Series. Treatment of obsessive-compulsive disorder. Journal of Clinical Psychiatry 58, suppl 4, 2-72.
85. Matsunaga H, Nagata T, Hayashida K, Ohya K, Kiriike N, Stein DJ (2009). A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. Journal of Clinical Psychiatry 70, 6, 863-868.
86. McDonough M, Kennedy N (2002). Pharmacological management of obsessive-compulsive disorder: a review for clinicians. Harvard Review of Psychiatry 10, 3, 127-137.
87. McDougle CJ, Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DS, Heninger GR (1990). Neuroleptic addition in fuvoxamine-refractory obsessive-compulsive disorder. American Journal of Psychiatry 147, 652-654.
88. McDougle CJ, Price LH, Goodman WK, Charney DS, Heninger GR (1991). A controlled trial of lithium augmentation in fuvoxamine-refractory obsessive-compulsive disorder: lack of effcacy. Journal of Clinical Psychopharmacology 11, 3, 175-184.
89. McDougle CJ, Goodman WK, Leckman JF, Holzer JC, Barr LC, McCance-Katz E, Heninger GR, Price LH (1993). Limited therapeutic effect of addition of buspirone in fuvoxamine-refractory obsessive-compulsive disorder. American Journal of Psychiatry 150, 4, 647-649.
90. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH (1994). Haloperidol addition in fuvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Archives of General Psychiatry 51, 4, 302-308.
91. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH (2000). A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Archives of General Psychiatry 57, 8, 794-801.
92. Mowla A, Khajeian AM, Sahraian A, Chohedri AH, Kashkoli F (2010). Topiramate Augmentation in Resistant OCD: A Double-Blind Placebo-Controlled Clinical Trial. CNS Spectrum, [Epub ahead of print].
93. Mundo E, Guglielmo E, Bellodi L (1998). Effect of adjuvant pindolol on the antiobsessional response to fuvoxamine: a double-blind, placebo-controlled study. International Clinical Psychopharmacology 13, 5, 219-224.
94. Muscatello MR, Bruno A, Pandolfo G, Micò U, Scimeca G, Romeo VM, Santoro V, Settineri S, Spina E, Zoccali RA (2011). Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology 31, 2, 174-179.
95. Ninan PT, Koran LM, Kiev A, Davidson JR, Rasmussen SA, Zajecka JM, Robinson DG, Crits-Christoph P, Mandel FS, Austin C (2006). High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. Journal of Clinical Psychiatry 67, 1, 15-22.
96. Nolen WA (2002). World Health Organization places psychiatry high on the agenda, also consequences for the Netherlands. Nederlands Tijdschrift voor Geneeskunde 146, 297-299.
97. Novelletto BF, Guzzinati S, Avogaro A (2012). Prevalence of metabolic syndrome and its relationship with clinically prevalent cardiovascular disease in the Veneto region, northeastern Italy. Metabolic Syndrome and Related Disorders 10, 1, 56-62.
98. Pallanti S, Quercioli L, Paiva RS, Koran LM (1999). Citalopram for treatment-resistant obsessive-compulsive disorder. European Psychiatry 14, 2, 101-106.
99. Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, Pato M, Stein D, Zohar J; International Treatment Refractory OCD Consortium (2002a). Treatment non response in OCD: methodological issues and operational definitions. International Journal of Neuropsychopharmacology 5, 2, 181-191.
100. Pallanti S, Quercioli L, Koran LM (2002b). Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. Journal of Clinical Psychiary 63, 9, 796-801.
101. Pallanti S, Quercioli L (2006). Treatment refractory obessive-compulsive disorder: methodological issues, operational defnitions and therapeuthic lines. Progress in Neuro-psychopharmacology and Biological Psychiatry 30, 400-412.
102. Pampaloni I, Sivakumaran T, Hawley CJ, Al Allaq A, Farrow J, Nelson S, Fineberg NA (2010). High-dose selective serotonin reuptake inhibitors in OCD: a systematic retrospective case notes survey. Journal of Psychopharmacology 24, 10, 1439-1445.
103. Pigott TA, Pato MT, Bernstein SE, Grover GN, Hill JL, Tolliver TJ, Murphy DL (1990). Controlled comparisons of clomipramine and fuoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results. Archives of General Psychiatry 47, 926-932.
104. Pigott TA, Pato MT, L'Heureux F, Hill JL, Grover GN, Murphy DL (1991). A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 11, 4, 242-248.
105. Pigott TA, L'Heureux F, Hill JL, Bihari K, Bernstein SE, Murphy DL (1992). A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 12, 1, 11-18.
106. Rabinowitz I, Baruch Y, Barak Y (2008). High-dose escitalopram for the treatment of obsessive-compulsive disorder. International Clinical Psychopharmacology 23, 1, 49-53.
107. Rasmussen SA, Eisen LJ, Pato MT (1993). Current issues in the pharmacologic management of obsessive-compulsive disorder. Journal of Clinical Psychiatry 54, 4-9.
108. Rauch SL, Jenike MA (1994). Management of treatment-resistant obsessive-compulsive disorder: concepts and strategies. In Hollander E, Zohar J, Marazziti D, Olivieri B (eds) Current insights in obsessive-compulsive disorder. John Wiley & Sons Ltd, Chichester.
109. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G (1995). Predictors of drug treatment response in obsessive-compulsive disorder. Journal of Clinical Psychiatry 56, 368-373.
110. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G (1996). Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Psychopharmacology Bulletin 32, 1, 167-173.
111. Rodrigues H, Figueira I, Gonçalves R, Mendlowicz M, Macedo T, Ventura P (2011). CBT for pharmacotherapy non-remitters--a systematic review of a next-step strategy. Journal of Affective Disorders 129, 1-3, 219-228.
112. Ruscio AM, Stein DJ, Chiu WT, Kessler RC (2010). The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Molecular Psychiatry 15, 1, 53-63.
113. Salvi V, Fagiolini A, Swartz HA, Maina G, Frank E (2008). The use of antidepressants in bipolar disorder. Journal of Clinical Psychiatry 69, 8, 1307-1318.
114. Sareen J, Kirshner A, Lander M, Kjernisted KD, Eleff MK, Reiss JP (2004). Do antipsychotics ameliorate or exacerbate Obsessive Compulsive Disorder symptoms? A systematic review. Journal of Affective Disorders 82, 2, 167-174.
115. Sayyah M, Sayyah M, Boostani H, Ghaffari SM, Hoseini A (2012). Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). Depression Anxiety 29, 10, 850-854.
116. Selvi Y, Atli A, Aydin A, Besiroglu L, Ozdemir P, Ozdemir O (2011). The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study. Human Psychopharmacology 26, 1, 51-57.
117. Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P, Goodman WK (2004). A double-blind, placebo-controlled trial of olanzapine addition in fuoxetine-refractory obsessive-compulsive disorder. Biological Psychiatry 55, 5, 553-555.
118. Skapinakis S, Papatheodorou T, Mavreas V (2007). Antipsychotic augmentation of serotoninergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. European Neuropsychopharmacology 17, 79-93.
119. Simeon JG, Thatte S, Wiggins D (1990). Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fuoxetine combination. Psychopharmacology Bulletin 26, 3, 285-290.
120. Simpson HB, Gorfnkle KS, Liebowitz MR (1999). Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial. Journal of Clinical Psychiatry 60, 9, 584-590.
121. Simpson HB, Foa EB, Liebowitz MR, Ledley DR, Huppert JD, Cahill S, Vermes D, Schmidt AB, Hembree E, Franklin M, Campeas R, Hahn CG, Petkova E (2008). A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmachoterapy in obsessive-compulsive disorder. American Journal of Psychiatry 165, 5, 621-630.
122. Soomro GM, Altman D, Rajagopal S, Oakley-Browne M (2008). Selective serotonin re-uptake inhibitors vs placebo for obsessive-compulsive disorder (OCD). Cochrane Database of Systematic Reviews 23, CD001765.
123. Stein DJ, Andersen EW, Tonnoir B, Fineberg N (2007). Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fxed-dose, 24-week study. Current Medical Research and Opinion 23, 701-711.
124. Tanner RM, Baber U, Carson AP, Voeks J, Brown TM, Soliman EZ, Howard VJ, Muntner P (2011) Association of the metabolic syndrome with atrial fbrillation among United States adults (from the REasons for Geographic and Racial Differences in Stroke [REGARDS] Study). American Journal of Cardiology 108, 2, 227-232.
125. Tolin DF, Maltby N, Diefenbach DJ, Hannan SE, Worhunsky P (2004). Cognitive-behavioral therapy for medication nonresponders with obsessive-compulsive disorder: a wait-list-controlled open trial. Journal of Clinical Psychiatry 65, 7, 922-931.
126. Tundo A, Salvati L, Busto G, Di Spigno D, Falcini R (2007). Addition of cognitive-behavioral therapy for nonresponder to medication for obsessive-compulsive disorder: a naturalistic study. Journal of Clinical Psychiatry 68, 10, 1552-1556.
127. van Noppen B, Steketee G (2003). Family response and multifamily behavioral treatment for obsessive-compulsive disorder. Brief Treatment and Crisis Intervention 3, 231-247.
128. van Noppen B, Steketee G, Pato M (1997). Group and multifamily behavioral treatments for OCD. In Hollander E, Stein D (Eds) Obsessive-compulsive disorder: diagnosis, etiology, treatment, 331-366. Marcel Dekker, New York.
129. Vulink NC, Denys D, Fluitman SB, Meinardi JC, Westenberg HG (2009). Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. Journal of Clinical Psychiatry 70, 7, 1001-1008.
130. Vulink NC, Figee M, Denys D (2011). Review of atypical antipsyhotic in anxiety. European Neuropsychopharmacology 21, 429-449.
131. Warneke LB (1989). Intravenous Chlorimipramine therapy in obsessive-compulsive disorder. Canadian Journal of Psychiatry 34, 853-859.
132. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R, Maercker A, van Os J, Preisig M, Salvador-Carulla L, Simon R, Steinhausen HC (2011). The size and the burden of mental disorders and other disorders in Europe 2010. European Neuropsychopharmacology 21, 9, 655-679.
133. Yaryura-Tobias JA, Neziroglu FA (1996). Venlafaxine in obsessive-compulsive disorder. Archives of General Psychiatry 53, 7, 653-654.
134. Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL (1987). Serotoninergic responsitivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Archives of General Psychiatry 44, 946-951.